Matches in Wikidata for { <http://www.wikidata.org/entity/Q58407576> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q58407576 description "A clinical trial related to cancer immunotherapy, retrieved from clinicaltrials.gov" @default.
- Q58407576 description "klinisch onderzoek" @default.
- Q58407576 name "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer" @default.
- Q58407576 name "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer" @default.
- Q58407576 name "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer" @default.
- Q58407576 type Item @default.
- Q58407576 label "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer" @default.
- Q58407576 label "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer" @default.
- Q58407576 label "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer" @default.
- Q58407576 prefLabel "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer" @default.
- Q58407576 prefLabel "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer" @default.
- Q58407576 prefLabel "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer" @default.
- Q58407576 P1050 Q58407576-917D9842-6E5E-483F-8422-1AC2DE5F6819 @default.
- Q58407576 P2899 Q58407576-0C8F3DD4-DAF0-4776-81E2-F7A925776CCD @default.
- Q58407576 P3098 Q58407576-605CD146-76C3-474F-A4D0-339327835297 @default.
- Q58407576 P31 Q58407576-2E0780B6-69B5-41B1-9744-A48430A4641A @default.
- Q58407576 P6153 Q58407576-7672D3E0-4D6A-48A2-81E6-292B151AD170 @default.
- Q58407576 P6153 Q58407576-7BBCBBEB-C376-4CED-9EC4-B13B1B9F58EF @default.
- Q58407576 P6153 Q58407576-95728583-6500-41CE-A6E8-45FDC89A5110 @default.
- Q58407576 P6153 Q58407576-9ADB3DAA-7157-40E2-9101-57AF6C86BDE3 @default.
- Q58407576 P6153 Q58407576-D54162BF-0FA0-4CA9-81D5-34E9921A3060 @default.
- Q58407576 P6153 Q58407576-D7A87B10-65EF-4679-89B7-3547F3B6B138 @default.
- Q58407576 P6153 Q58407576-DC680664-82CB-4700-BBE6-692EB9551BC6 @default.
- Q58407576 P8363 Q58407576-39AD101C-8D04-4176-B8BA-D4AE43E214B8 @default.
- Q58407576 P921 Q58407576-02CF5DF7-0EDF-4515-AB86-07AA4108FA64 @default.
- Q58407576 P1050 Q15124212 @default.
- Q58407576 P2899 "+18" @default.
- Q58407576 P3098 "NCT02250326" @default.
- Q58407576 P31 Q30612 @default.
- Q58407576 P6153 Q16993822 @default.
- Q58407576 P6153 Q16996755 @default.
- Q58407576 P6153 Q5555028 @default.
- Q58407576 P6153 Q5637237 @default.
- Q58407576 P6153 Q586694 @default.
- Q58407576 P6153 Q777403 @default.
- Q58407576 P6153 Q94198629 @default.
- Q58407576 P8363 Q78089383 @default.
- Q58407576 P921 Q2012719 @default.